These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 17882685

  • 21. Safety and benefit considerations for menopausal hormone therapy.
    Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS.
    Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
    [Abstract] [Full Text] [Related]

  • 22. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Alternatives for optimal hormone replacement therapy.
    Sitruk-Ware R.
    Climacteric; 2003 Aug; 6 Suppl 2():11-6. PubMed ID: 14669839
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
    Lilue M, Palacios S.
    Ginecol Obstet Mex; 2009 Oct; 77(10):475-81. PubMed ID: 19902676
    [Abstract] [Full Text] [Related]

  • 28. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH, Gallagher JC.
    Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
    [Abstract] [Full Text] [Related]

  • 29. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K.
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [Abstract] [Full Text] [Related]

  • 30. The case for progesterone.
    Stein DG.
    Ann N Y Acad Sci; 2005 Jun; 1052():152-69. PubMed ID: 16024758
    [Abstract] [Full Text] [Related]

  • 31. Testosterone patch: new drug. Don't use to stimulate women's sexual desire.
    Prescrire Int; 2007 Oct; 16(91):190-2. PubMed ID: 17926827
    [Abstract] [Full Text] [Related]

  • 32. Transdermal testosterone for women: a new physiological approach for androgen therapy.
    Mazer NA, Shifren JL.
    Obstet Gynecol Surv; 2003 Jul; 58(7):489-500. PubMed ID: 12832941
    [Abstract] [Full Text] [Related]

  • 33. Endometrial safety and bleeding with HRT: what's new?
    Sturdee DW.
    Climacteric; 2007 Oct; 10 Suppl 2():66-70. PubMed ID: 17882676
    [Abstract] [Full Text] [Related]

  • 34. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM, Faustmann T.
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [Abstract] [Full Text] [Related]

  • 35. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.
    Kung AW, Chu EY, Xu L.
    Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558
    [Abstract] [Full Text] [Related]

  • 36. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A, Piette JC.
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [Abstract] [Full Text] [Related]

  • 37. Why are physicians reluctant to use estrogens for anything--or do they prefer 'PROFOX'?
    Studd J.
    Menopause Int; 2009 Jun; 15(2):52-4. PubMed ID: 19465668
    [Abstract] [Full Text] [Related]

  • 38. Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).
    Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG.
    Am J Cardiol; 2008 Sep 15; 102(6):693-9. PubMed ID: 18773990
    [Abstract] [Full Text] [Related]

  • 39. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E, Canfell K.
    Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078
    [Abstract] [Full Text] [Related]

  • 40. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M, Simoncini T, Fuller S, Genazzani AR.
    Maturitas; 2008 Jul 01; 60(3-4):185-201. PubMed ID: 18775609
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.